about
Update on pulmonary disease due to non-tuberculous mycobacteriaInfluence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosisStrategies for treating latent multiple-drug resistant tuberculosis: a decision analysisPotential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infectionInhaled azithromycin therapy.Extrapulmonary tuberculosis, human immunodeficiency virus, and foreign birth in North Carolina, 1993 - 2006.HIV-specific health care utilization and mortality among tuberculosis/HIV coinfected persons.Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.The human antibody response to the surface of Mycobacterium tuberculosis.Geographic information system-based screening for TB, HIV, and syphilis (GIS-THIS): a cross-sectional study.Nontuberculous mycobacterial infection after fractionated CO(2) laser resurfacing.Discriminating between latent and active tuberculosis with multiple biomarker responses.Community-based HCV screening: knowledge and attitudes in a high risk urban populationA randomized controlled trial of standard versus intensified tuberculosis diagnostics on treatment decisions by physicians in Northern Tanzania.Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.Current issues in global tuberculosis control.Whole genome sequencing identifies circulating Beijing-lineage Mycobacterium tuberculosis strains in Guatemala and an associated urban outbreak.Cavitary pulmonary disease.Mental Health and Substance Use Among Patients in a North Carolina HIV Clinic.Association between 16S-23S internal transcribed spacer sequence groups of Mycobacterium avium complex and pulmonary disease.Alcohol use and clinical manifestations of tuberculosis.Nontuberculous mycobacterial olecranon bursitis: case reports and literature review.Barriers to using text message appointment reminders in an HIV clinic.Advances in the management of pulmonary disease due to Mycobacterium abscessus complex.Twenty-eight cases of Mycobacterium marinum infection: retrospective case series and literature review.Increasing Nocardia Incidence Associated with Bronchiectasis at a Tertiary Care Center.Increased prevalence of advanced tuberculosis in rural low tuberculosis caseload counties in North Carolina.Clinical utility of indium 111-labeled white blood cell scintigraphy for evaluation of suspected infection.A Breath of Fresh Air for Patients with Pulmonary Nontuberculous Mycobacterial Infection.Macrophage Epithelial Reprogramming Underlies Mycobacterial Granuloma Formation and Promotes Infection.Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis.Getting to a Man's Heart through His Colon.Medium matters: modeling the impact of solid medium performance on tuberculosis trial sample size requirementsEpidemiology of nontuberculous mycobacteria isolations among central North Carolina residents, 2006-2010.The complexities of Xpert® MTB/RIF interpretation.Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.Hepatitis B core antibody-positive donors in cardiac transplantation: a single-center experience.Treatment of Mycobacterium abscessus: all macrolides are equal, but perhaps some are more equal than othersSafety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
P50
Q26765786-0EA32B90-A46F-4626-9E0C-80C0CC757BD7Q28474010-A238EE4D-DEB8-46B0-B873-817522E369A1Q28478920-B93F89B5-DEFF-4086-8E43-F2B48ED196B3Q28479103-1FB63E2E-B5D9-4757-94D6-6EC9E6528B2FQ33237163-415F6F78-8C81-4434-A45F-02DE18F0143AQ33327171-BECD7C13-93BE-422B-BFC2-F42D6DCC247EQ33705696-5D866802-881C-4A3B-9EAA-0715C05C941AQ33735589-9AC71C09-3312-4071-8AF6-1CC17FF98F82Q33740190-321DF323-6242-4705-BFD1-DB1DC64E56CCQ34441057-BE222E05-55EF-4D2F-91F9-47AF294EAC9EQ34694553-BAA0064B-C1AE-469B-B5A4-4298B779B48CQ34958633-A69B8EB4-97AD-4ED0-9DC9-79967E8D02F7Q35089934-CF51CE89-7E5A-42A8-AF6A-E19EB75F2F84Q35098082-900EC062-36FA-4FD3-B444-438AE15A9B64Q35779318-47094811-FFE8-4EC4-89EC-7C89D231F087Q36267462-925A0605-F686-45C1-80C2-E93F44899983Q36355339-91B8DF5D-4CE0-4401-824A-296EEB5B5B1EQ36538804-496F64F4-1887-4267-9290-66FD6B1F58B5Q36636239-0CADEA60-A544-403C-8753-572EE11B2717Q36845423-C3B8CD7D-BBAB-4142-84C3-8817D497D9E4Q37087413-9C9E8101-216E-41E8-927F-8B23D55418B6Q37329671-DB5CFF89-D429-4F05-97D1-0516F8AF417BQ37430629-18D3D70C-2F34-4C6B-9443-FD2F70849AB6Q38248727-76824EEF-29FC-4DF3-80CC-85121F0282C0Q38419361-FDF96BD6-70FA-43B5-98C9-EB78F41CC661Q38946048-4D250565-8214-47E4-9C64-D71053A4C180Q40003357-5D545738-3DA9-4E52-AD14-BD43CAB0CAB8Q40167094-F463DF4D-EE7C-41CF-BA86-D8EFB23ECD15Q40293783-2E2A6F49-F3BB-4A9E-A9DB-1FC9009F9062Q40498003-0869FD31-5204-4049-AE2C-2EB9567E59D0Q40683731-E7486871-3ABA-4BC4-9583-F124F9521D69Q40694322-547D0C80-C5F7-4084-AC9C-8A2F0D05B54BQ40711897-32D667F3-49F9-4D54-A4F4-D380BC42A9C3Q40747840-D3729FBE-C49B-469A-AE92-B290F17D925FQ41481079-4D6CAB51-BE85-4FA9-AFDC-780A6959702AQ42110466-79CAA40F-FB88-4649-A189-D8EE25D46E07Q42198117-04F5254A-88EA-4168-96A0-94BA6EFE2995Q42428577-AE430D0A-E1B3-4E52-B9FF-C3885B2731A8Q44225838-D73FD79B-7D42-4C59-99E9-EB7F4CDF37BAQ44776728-4462B1BA-A1AF-4EEA-923C-4FB14A198C1C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jason E. Stout
@ast
Jason E. Stout
@en
Jason E. Stout
@es
Jason E. Stout
@nl
Jason E. Stout
@sl
type
label
Jason E. Stout
@ast
Jason E. Stout
@en
Jason E. Stout
@es
Jason E. Stout
@nl
Jason E. Stout
@sl
altLabel
jason e stout
@en
jason stout
@en
stout j
@en
stout je
@en
prefLabel
Jason E. Stout
@ast
Jason E. Stout
@en
Jason E. Stout
@es
Jason E. Stout
@nl
Jason E. Stout
@sl
P106
P1153
7201718463
P21
P31
P496
0000-0002-6698-8176